Ratings by Barclays (Emmanuel Papadakis)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/6/2026 | Novartis | NVS | Upgrade | Equalweight (Underweight) |
137.91 (160.12) |
16.1% | Details | |
| 12/7/2018 | Novartis | NVS | Downgrade | Underweight (Equalweight) |
89.05 (137.91) |
54.87% | Details |
